PeptideNerds
· GLP-1 Peptides · 24 min read

Retatrutide: The Complete Guide to the Triple Agonist Peptide

Alejandro Reyes

Written by Alejandro Reyes

Founder & Lead Researcher

PN

Reviewed by Peptide Nerds Editorial · Updated March 2026

Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.

Retatrutide: The Complete Guide to the Triple Agonist Peptide

Retatrutide is the most talked-about drug in the GLP-1 pipeline right now. And for good reason.

Phase 2 data showed weight loss of up to 24.2% of body weight at 48 weeks. That number would make it the most effective weight loss compound ever tested in a controlled trial. No approved drug has come close.

Phase 3 is underway. Eli Lilly's TRIUMPH program has seven trials running simultaneously. The data is expected in 2026.

This page is our running reference for everything retatrutide: how it works, what the trials show, how it compares to existing drugs, and what access looks like now and after potential approval. You can also browse all of our retatrutide coverage on the retatrutide hub.

We update this page as new data becomes available.

Key Takeaways

  • Retatrutide is a triple agonist developed by Eli Lilly. It activates GIP, GLP-1, and glucagon receptors simultaneously.
  • Phase 2 results showed up to 24.2% body weight loss at 48 weeks, the highest number ever recorded in a clinical weight loss trial.
  • Seven Phase 3 trials are running under the TRIUMPH program. Results are expected throughout 2026.
  • Retatrutide is not FDA-approved. It cannot be legally obtained outside of clinical trials.
  • Early data suggests benefits beyond weight loss, including liver fat reduction and potential metabolic improvements.

What Is Retatrutide?

Retatrutide is an investigational peptide drug developed by Eli Lilly. It is designed as a triple receptor agonist, meaning it activates three separate hormone receptors involved in metabolic regulation:

  • GIP receptor (glucose-dependent insulinotropic polypeptide)
  • GLP-1 receptor (glucagon-like peptide-1)
  • Glucagon receptor

That third receptor is what makes retatrutide distinct. No approved drug targets all three.

To understand why that matters, here is a detailed look at what each receptor pathway actually does in the body.

The GLP-1 Receptor: Appetite and Gastric Emptying

GLP-1 stands for glucagon-like peptide-1. It is a hormone produced by L-cells in the small intestine in response to food. GLP-1 receptor agonism is the engine behind Ozempic, Wegovy, and the weight loss effects of semaglutide.

In the brain, GLP-1 signals the hypothalamus to reduce appetite and calorie intake. In the gut, GLP-1 slows gastric emptying, extending the feeling of fullness after a meal and blunting post-meal glucose spikes. In the pancreas, GLP-1 stimulates insulin secretion in a glucose-dependent manner, reducing hypoglycemia risk compared to older diabetes drugs.

By itself, GLP-1 receptor agonism produces roughly 10-17% body weight reduction in clinical trials depending on dose and formulation.

The GIP Receptor: Insulin Enhancement and Lipid Metabolism

GIP stands for glucose-dependent insulinotropic polypeptide. It is produced by K-cells in the upper small intestine and plays a complementary role to GLP-1 in regulating metabolism after meals.

GIP's primary function is to amplify insulin secretion. After a meal, GIP and GLP-1 work together to produce what researchers call the "incretin effect," which is the enhanced insulin response you get from eating food orally compared to having glucose delivered intravenously. GIP accounts for roughly 50-70% of that effect in healthy people (PMID 32628294).

Beyond insulin, GIP influences lipid (fat) metabolism in adipose tissue. Research suggests GIP receptor activation may support beta-cell preservation and proliferation, which has implications for long-term glucose regulation in people with type 2 diabetes (PMID 24292195).

Tirzepatide was the first approved drug to combine GLP-1 and GIP receptor agonism. Head-to-head trials showed it outperformed semaglutide alone in both weight loss and glycemic control, reaching approximately 20-22% body weight reduction.

The Glucagon Receptor: Energy Expenditure and Liver Fat

The glucagon receptor is the new variable, and where retatrutide's mechanism diverges most significantly from tirzepatide.

Glucagon is a hormone produced by alpha cells in the pancreas. Its classic function is the opposite of insulin: when blood sugar drops, glucagon signals the liver to release stored glucose. But glucagon does a great deal more than manage blood sugar. At physiological doses relevant to retatrutide's receptor activation, three mechanisms are particularly relevant:

Energy expenditure. Glucagon receptor activation raises resting metabolic rate. It does this in part by stimulating thermogenesis in brown adipose tissue, the type of fat tissue that burns energy to generate heat. Research suggests glucagon agonism can increase total energy expenditure in ways that GLP-1 and GIP activation do not fully replicate (PMID 28528829).

Hepatic fat oxidation. Glucagon promotes fat burning in the liver (hepatic lipid oxidation). This is particularly relevant for metabolic-associated steatotic liver disease (MASLD). The liver connection is one reason retatrutide has shown striking results in liver fat reduction. Phase 2 data showed an 86% reduction in liver fat at 24 weeks at the 12 mg dose.

Appetite suppression via separate pathways. Glucagon receptors in the brain, particularly in the hypothalamus and brainstem, appear to reinforce the appetite-reducing signals from GLP-1. These pathways are distinct enough that combining them may not simply be additive but potentially synergistic.

The challenge with glucagon is that at high doses, it raises blood sugar. Retatrutide's design mitigates this through careful receptor agonism calibrated so that the metabolic benefits are achieved without triggering hyperglycemia. GLP-1 and GIP co-activation help offset the glucose-raising effect by stimulating insulin release.

Why Triple Is More Than the Sum of Its Parts

The case for combining all three receptors is not just that each one does something useful individually. It is that the three pathways interact in ways that amplify each other's effects. Reducing intake (GLP-1/GIP) and increasing expenditure (glucagon) simultaneously should produce greater energy deficit than either approach alone. The Phase 2 data suggests this is playing out in practice.

Dysesthesia: A Novel Side Effect

One side effect reported more frequently with retatrutide compared to other GLP-1 class drugs is dysesthesia, an abnormal skin sensation often described as tingling or burning, reported in 8.8-20.9% of participants in Phase 2 depending on dose. This is a novel side effect pattern that researchers are continuing to characterize in Phase 3.

For a detailed breakdown of its pharmacology, see our compound data page: Retatrutide: Compound Profile.

Clinical Trial Results

Phase 2 Results

The Phase 2 data for retatrutide is what put this drug on the map.

The landmark Phase 2 trial published in 2023 tested multiple doses in adults with obesity. At the highest dose tier at 48 weeks, participants experienced up to 24.2% body weight loss. Lower dose groups showed meaningful results as well, with one Phase 2 cohort showing approximately 8.96 kg weight loss at shorter durations.

A separate analysis reported weight loss outcomes at 36 weeks across dose groups, showing a consistent dose-response relationship. Higher doses produced greater weight loss, and the trajectory at 48 weeks had not yet reached a clear plateau in the highest dose group.

One early research note: these are Phase 2 results with smaller patient populations than Phase 3. The participant counts are in the hundreds, not thousands. Phase 3 is designed to confirm whether these numbers hold in a larger, more diverse population.

Phase 3: The TRIUMPH Program

Eli Lilly launched the TRIUMPH program to carry retatrutide through Phase 3. Seven trials are currently running.

The TRIUMPH-4 trial design was published in a peer-reviewed paper (PMID 41090431), which gives us the structural blueprint. Eli Lilly announced a 26.6% placebo-adjusted weight loss figure from TRIUMPH-4, but the peer-reviewed results paper for this readout has not yet been published as of March 2026. We are noting that distinction clearly. Sponsor-announced results and peer-reviewed publications are not the same thing, and we will update this section when the data goes through formal peer review.

The full TRIUMPH program covers weight loss, cardiovascular outcomes, metabolic dysfunction-associated steatohepatitis (MASH), sleep apnea, and other conditions. That breadth reflects how comprehensive the regulatory package needs to be before FDA would consider approval.

For the most current trial status and enrollment information, see our dedicated page: Retatrutide Clinical Trials 2026.

For a deeper breakdown of what the weight loss data shows across every dose group and timepoint, see: Retatrutide Weight Loss Results.

How Retatrutide Compares

The honest comparison question is not whether retatrutide outperforms existing drugs. Phase 2 data suggests it does on weight loss. The real questions are: by how much, for whom, and with what trade-offs?

Here is where the evidence stands across the four most-discussed compounds:

Drug Developer Mechanism Peak Weight Loss (Published Data) Status
Semaglutide 2.4 mg (Wegovy) Novo Nordisk GLP-1 agonist ~15-17% (STEP 1) FDA-approved
Tirzepatide 15 mg (Zepbound) Eli Lilly GLP-1 + GIP dual agonist ~20-22% (SURMOUNT-1) FDA-approved
Retatrutide Eli Lilly GLP-1 + GIP + glucagon triple agonist Up to 24.2% (Phase 2, 48 weeks) Phase 3 / Investigational
Survodutide Boehringer Ingelheim GLP-1 + glucagon dual agonist ~18.7% (Phase 2) Phase 3 / Investigational

A few important caveats on this table.

These numbers come from different trials with different patient populations, doses, durations, and dropout handling methods. They are useful for directional comparison, not precise ranking. Head-to-head trial data between these compounds does not exist for most pairings.

Retatrutide's 24.2% figure is from Phase 2 at 48 weeks. Tirzepatide's 20-22% is from Phase 3 at 72 weeks in the SURMOUNT-1 trial. The retatrutide trial ran for fewer weeks with a smaller population. Those are meaningful differences.

On mechanism: the additional glucagon receptor targeting in retatrutide is what separates it from tirzepatide. Both drugs target GIP and GLP-1. Retatrutide adds glucagon. The clinical significance of that third target, in terms of real-world outcomes, is what Phase 3 is designed to quantify.

For detailed head-to-head comparisons:

Retatrutide for Weight Loss

Who Was Studied

Phase 2 trials enrolled adults with a BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related health condition. That is consistent with the eligibility criteria used for tirzepatide and semaglutide trials, and likely reflects what FDA approval would require as the indicated population.

Participants did not have Type 2 diabetes in the primary obesity Phase 2 trial. Separate trials are evaluating retatrutide in Type 2 diabetes populations.

What the Weight Loss Timeline Looks Like

Based on Phase 2 data, weight loss appears to continue through 48 weeks without a clear plateau at the highest doses. This is different from what some earlier GLP-1 drugs showed, where weight loss leveled off by 20-24 weeks.

A Phase 2 analysis published in 2023 showed dose-dependent results at 36 weeks across the tested dose range, confirming that the relationship between dose and outcome is consistent. Body composition data from Phase 2 shows fat mass reductions of -15.2%, -26.1%, and -23.2% across dose tiers, suggesting the weight lost is predominantly fat mass rather than lean mass, though Phase 3 body composition data will be needed to confirm this at scale.

Side Effect Profile

GI side effects are the primary concern across all GLP-1 class drugs, and retatrutide is no exception. Phase 2 data showed nausea, vomiting, and diarrhea as the most common adverse events, with incidence that tracked with dose escalation. Most events were mild to moderate in severity.

The glucagon receptor component raises a separate question about hepatic effects and energy metabolism. Early data does not raise major safety signals, but Phase 3 safety data across thousands of participants will be the definitive source.

For a full breakdown of what Phase 2 reported on tolerability and what to watch for, see: Retatrutide Side Effects: What to Expect.

For a dedicated look at who retatrutide may benefit most and what the realistic expectations are, see: Retatrutide for Weight Loss.

How to Get Retatrutide

The direct answer: you cannot get retatrutide legally outside of a clinical trial as of March 2026. It is not FDA-approved. It is not available as a prescription. Compounding pharmacies cannot legally produce a drug that is not FDA-approved for a non-research purpose.

There are three legitimate ways to access retatrutide right now:

1. Enroll in a TRIUMPH clinical trial. Eli Lilly is actively recruiting for multiple Phase 3 sites. Eligibility varies by trial. Start at ClinicalTrials.gov to find open sites near you. Participation is free, and participants receive the drug and monitoring at no cost.

2. Wait for FDA approval. If Phase 3 data supports an approval, Eli Lilly would submit an NDA (New Drug Application) to the FDA. Review typically takes 12-18 months after submission. Based on current timelines, the earliest realistic commercial availability is 2028, and that assumes Phase 3 data is strong and no unexpected safety signals emerge.

3. Avoid gray-market sources. Retatrutide is appearing on research chemical sites labeled "for research use only." The risks here are significant: no quality control, no dosing verification, no oversight, and legal exposure in many jurisdictions. We cover the regulatory landscape in detail at How to Get Retatrutide.

Cost Estimates

Retatrutide does not have a commercial price. Estimates based on the pricing of comparable drugs suggest it would land somewhere between $800 and $1,400 per month at list price without insurance, depending on dose and competitive pressure at launch.

The actual price will depend heavily on insurance coverage, whether generics or biosimilars emerge after patent expiration, and how Eli Lilly prices it relative to tirzepatide (which they also make). For the full cost analysis, see: Retatrutide Cost: What to Expect.

Retatrutide and Other Conditions

Weight loss is the headline, but retatrutide's mechanism suggests potential benefits for several metabolic conditions. Here is what the research shows so far.

Liver Health (MASH/NAFLD)

This is one of the most compelling non-weight-loss signals in the retatrutide data.

A Phase 2 study examining liver fat showed an 86% reduction in liver fat at 24 weeks at the 12mg dose. MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) is a condition with very few effective treatment options. An 86% reduction in liver fat is a striking number.

The TRIUMPH program includes a dedicated MASH trial. This is one of the more medically significant indications being studied. For more on this data, see: Retatrutide for Liver Health: MASH and NAFLD.

Sleep Apnea

Obesity is the primary driver of obstructive sleep apnea in most patients. Weight loss interventions consistently improve sleep apnea severity. Tirzepatide's SURMOUNT-OSA trial showed significant improvements in apnea-hypopnea index scores.

The TRIUMPH program includes a sleep apnea trial for retatrutide. We expect to see similar improvements given the degree of weight loss observed, but the trial data has not yet been published. For current coverage, see: Retatrutide and Sleep Apnea.

Cardiovascular Outcomes

Cardiovascular outcomes trials are a standard component of FDA approval packages for metabolic drugs. The TRIUMPH program includes cardiovascular outcome data. No published results are available as of March 2026.

Cancer Research Note

One preclinical study examined retatrutide in mouse models in the context of cancer biology (PMID 40094000). This study was conducted in mouse models only. There is no human cancer data for retatrutide. Preclinical findings do not translate directly to human outcomes. We mention it here only because it appears in research discussions and we want to be accurate about what level of evidence exists.

All Retatrutide Content on This Site

In-Depth Coverage

Condition-Specific Coverage

Comparisons

Compound Data

Frequently Asked Questions {#faq}

When will retatrutide be FDA-approved?

No FDA approval date has been announced. The TRIUMPH Phase 3 program is ongoing as of March 2026. Eli Lilly would need to complete the trials, compile the data package, and submit a New Drug Application. FDA review typically takes 12-18 months after submission. The earliest realistic commercial availability is 2028, assuming the Phase 3 data supports a submission and the review proceeds without major delays.

How much weight can you lose on retatrutide?

Phase 2 data showed up to 24.2% body weight loss at 48 weeks at the highest dose tested, based on published research (PMID 37366315). Eli Lilly has announced a 26.6% placebo-adjusted weight loss figure from the TRIUMPH-4 Phase 3 trial, but that result has not yet been published in a peer-reviewed journal as of March 2026. Individual results in any trial vary by dose, duration, lifestyle factors, and individual biology.

Is retatrutide better than Ozempic?

Based on Phase 2 data, retatrutide produces substantially more weight loss than semaglutide (Ozempic/Wegovy) at comparable timepoints. Semaglutide achieves roughly 15-17% body weight reduction. Retatrutide's Phase 2 top-line result was 24.2% at 48 weeks. The mechanisms are also different: semaglutide targets only the GLP-1 receptor, while retatrutide targets GLP-1, GIP, and glucagon. That said, direct head-to-head trial data does not exist, and Ozempic is FDA-approved while retatrutide is not. See our full breakdown at Retatrutide vs Ozempic.

What makes retatrutide different from tirzepatide?

Both drugs are made by Eli Lilly and both target GIP and GLP-1 receptors. Retatrutide adds a third target: the glucagon receptor. Glucagon receptor agonism, in combination with GLP-1 activation, appears to increase energy expenditure in ways that single or dual agonism does not. That third mechanism is the key variable being tested in Phase 3. See the full comparison at Retatrutide vs Tirzepatide.

What are the side effects of retatrutide?

Phase 2 data showed that GI side effects were the most common: nausea, vomiting, and diarrhea, particularly during dose escalation. This is consistent with the GLP-1 class broadly. Most events were mild to moderate. The Phase 3 safety database will be much larger and will provide a clearer picture of rare adverse events and long-term tolerability. For a full review, see Retatrutide Side Effects: What to Expect.

How much will retatrutide cost?

Retatrutide does not have a commercial price yet. Based on comparable drugs, estimates range from $800 to $1,400 per month at list price. The actual cost will depend on insurance coverage, whether Eli Lilly uses a similar pricing strategy to tirzepatide, and competitive dynamics at the time of launch. For the full analysis, see Retatrutide Cost.

Can you get retatrutide now?

Not legally, outside of a clinical trial. Retatrutide is an investigational drug. It cannot be prescribed. Research chemical suppliers sell substances labeled "retatrutide" but these are unregulated, unverified, and carry significant safety and legal risks. The legitimate path is enrolling in a TRIUMPH trial via ClinicalTrials.gov. See the full access guide at How to Get Retatrutide.

Is retatrutide a GLP-1?

Yes, partially. Retatrutide activates the GLP-1 receptor, which is why it is often grouped with GLP-1 drugs. But it also activates GIP and glucagon receptors, which makes it more accurately described as a triple agonist rather than a GLP-1 drug. The GLP-1 component contributes appetite suppression and metabolic effects. The GIP and glucagon components add additional mechanisms that existing GLP-1 drugs do not have.

What is the TRIUMPH program?

TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. It consists of seven trials evaluating retatrutide across different populations and conditions: obesity, Type 2 diabetes, MASH, sleep apnea, and cardiovascular outcomes. The scale of the program reflects how comprehensive the FDA submission package will need to be. For trial-by-trial status, see Retatrutide Clinical Trials 2026.

What is retatrutide's liver fat data?

A Phase 2 study showed an 86% reduction in liver fat at 24 weeks at the 12mg dose in participants with elevated liver fat at baseline. This is one of the most striking findings in the retatrutide data set outside of weight loss. MASH is a condition with limited effective treatments, and a Phase 3 MASH trial is underway. For the full breakdown, see Retatrutide for Liver Health.

Stay Current on Retatrutide

Phase 3 results are expected throughout 2026. We update this page as data is published.

Get retatrutide updates as they happen. Phase 3 results, FDA decisions, access guides, delivered weekly to your inbox.

Subscribe to the Peptide Nerds newsletter

Medical Disclaimer

The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The editorial team reports on published research findings, not medical recommendations. Retatrutide is an investigational drug and is not FDA-approved for any indication as of the publication date of this article.

Sources

  1. Retatrutide Phase 2 obesity trial: up to 24.2% weight loss at 48 weeks. PMID 37366315. New England Journal of Medicine, 2023.
  2. Retatrutide Phase 2 weight loss outcomes at lower dose. PMID 36354040. Early Phase 2 cohort data.
  3. Retatrutide weight loss at 36 weeks across dose groups. PMID 37385280. Dose-response analysis.
  4. TRIUMPH-4 trial design paper. PMID 41090431. Published trial design; Phase 3 results pending peer-reviewed publication.
  5. Retatrutide liver fat reduction: 86% at 24 weeks, 12mg dose. PMID 38858523. Phase 2 liver fat substudy.
  6. Retatrutide fat mass reductions across dose tiers. PMID 40609566. Body composition analysis.
  7. Retatrutide preclinical cancer study in mouse models. PMID 40094000. Mouse model only; no human cancer data.
  8. Tirzepatide SURMOUNT-1 Phase 3 trial. PMID 35658024. Reference for tirzepatide weight loss benchmark.
  9. Semaglutide STEP 1 Phase 3 trial. PMID 33567185. Reference for semaglutide weight loss benchmark.

Schema Markup

{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://peptidenerds.com/#organization",
      "name": "Peptide Nerds",
      "url": "https://peptidenerds.com",
      "logo": {
        "@type": "ImageObject",
        "url": "https://peptidenerds.com/logo.png"
      },
      "sameAs": [
        "https://instagram.com/fatmaninthearena"
      ]
    },
    {
      "@type": "MedicalWebPage",
      "@id": "https://peptidenerds.com/retatrutide-complete-guide#article",
      "headline": "Retatrutide: The Complete Guide to the Triple Agonist Peptide",
      "datePublished": "2026-03-11T08:00:00-05:00",
      "dateModified": "2026-03-11T08:00:00-05:00",
      "author": {
        "@type": "Organization",
        "name": "Peptide Nerds Editorial Team",
        "url": "https://peptidenerds.com/about"
      },
      "publisher": {
        "@id": "https://peptidenerds.com/#organization"
      },
      "description": "Everything about retatrutide in one place. Phase 3 trial tracker, weight loss results, comparisons, cost estimates, and access guide. Updated March 2026.",
      "mainEntityOfPage": {
        "@type": "WebPage",
        "@id": "https://peptidenerds.com/retatrutide-complete-guide"
      },
      "medicalAudience": {
        "@type": "MedicalAudience",
        "audienceType": "Patient"
      }
    },
    {
      "@type": "FAQPage",
      "@id": "https://peptidenerds.com/retatrutide-complete-guide#faq",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "When will retatrutide be FDA-approved?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "No FDA approval date has been announced. The TRIUMPH Phase 3 program is ongoing as of March 2026. Eli Lilly would need to complete the trials, compile the data package, and submit a New Drug Application. FDA review typically takes 12-18 months after submission. The earliest realistic commercial availability is 2028, assuming Phase 3 data supports a submission and review proceeds without major delays."
          }
        },
        {
          "@type": "Question",
          "name": "How much weight can you lose on retatrutide?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Phase 2 data showed up to 24.2% body weight loss at 48 weeks at the highest dose tested. Eli Lilly announced a 26.6% placebo-adjusted figure from TRIUMPH-4, but that result has not yet been published in a peer-reviewed journal as of March 2026. Individual results vary by dose, duration, and individual biology."
          }
        },
        {
          "@type": "Question",
          "name": "Is retatrutide better than Ozempic?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Based on Phase 2 data, retatrutide produces substantially more weight loss than semaglutide (Ozempic/Wegovy). Semaglutide achieves roughly 15-17% body weight reduction. Retatrutide's Phase 2 top result was 24.2% at 48 weeks. Direct head-to-head trial data does not exist, and Ozempic is FDA-approved while retatrutide is not."
          }
        },
        {
          "@type": "Question",
          "name": "What makes retatrutide different from tirzepatide?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Both drugs are made by Eli Lilly and both target GIP and GLP-1 receptors. Retatrutide adds a third target: the glucagon receptor. Glucagon receptor agonism, combined with GLP-1 activation, appears to increase energy expenditure in ways dual agonism does not. That third mechanism is the key variable being tested in Phase 3."
          }
        },
        {
          "@type": "Question",
          "name": "What are the side effects of retatrutide?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Phase 2 data showed GI side effects as the most common: nausea, vomiting, and diarrhea, particularly during dose escalation. Most events were mild to moderate in severity. This is consistent with the GLP-1 class broadly. Phase 3 safety data across thousands of participants will provide a clearer picture of rare adverse events and long-term tolerability."
          }
        },
        {
          "@type": "Question",
          "name": "How much will retatrutide cost?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Retatrutide does not have a commercial price yet. Based on comparable drugs, estimates range from $800 to $1,400 per month at list price. The actual cost will depend on insurance coverage, competitive dynamics at launch, and Eli Lilly's pricing strategy relative to tirzepatide."
          }
        },
        {
          "@type": "Question",
          "name": "Can you get retatrutide now?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Not legally, outside of a clinical trial. Retatrutide is an investigational drug and cannot be prescribed. The legitimate path is enrolling in a TRIUMPH trial via ClinicalTrials.gov. Research chemical suppliers sell substances labeled as retatrutide, but these are unregulated and carry significant safety and legal risks."
          }
        },
        {
          "@type": "Question",
          "name": "Is retatrutide a GLP-1?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Yes, partially. Retatrutide activates the GLP-1 receptor, but it also activates GIP and glucagon receptors, making it more accurately described as a triple agonist. The GLP-1 component contributes appetite suppression and metabolic effects. The GIP and glucagon components add mechanisms that existing GLP-1 drugs do not have."
          }
        },
        {
          "@type": "Question",
          "name": "What is the TRIUMPH program?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. It consists of seven trials evaluating retatrutide across different populations and conditions: obesity, Type 2 diabetes, MASH, sleep apnea, and cardiovascular outcomes. Results are expected throughout 2026."
          }
        },
        {
          "@type": "Question",
          "name": "What is retatrutide's liver fat data?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "A Phase 2 study showed an 86% reduction in liver fat at 24 weeks at the 12mg dose in participants with elevated liver fat at baseline. This is one of the most significant findings in the retatrutide data set outside of weight loss. A Phase 3 MASH trial is currently underway."
          }
        }
      ]
    },
    {
      "@type": "BreadcrumbList",
      "@id": "https://peptidenerds.com/retatrutide-complete-guide#breadcrumb",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://peptidenerds.com"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "GLP-1 Peptides",
          "item": "https://peptidenerds.com/glp-1-peptides"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Retatrutide: The Complete Guide",
          "item": "https://peptidenerds.com/retatrutide-complete-guide"
        }
      ]
    }
  ]
}

Free Peptide Weight Loss Guide

Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.

Related articles

How to Get Retatrutide: Current Access Pathways Explained

March 22, 2026 · 25 min read

Retatrutide Cost: What to Expect When It Hits the Market

March 22, 2026 · 17 min read

Retatrutide vs. Tirzepatide: Triple Agonist vs. Dual Agonist. What the Research Shows

March 22, 2026 · 20 min read